Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) are the two stocks most typically associated with obesity drugs, but diabetes-drug maker Novo Nordisk (NYSE:NVO) is also trying to enter this space. The company is completing phase 3 clinical trials in an attempt to get Victoza approved as a weight-loss drug for obese and overweight patients with type 2 diabetes.
After reporting data from a clinical study today, shares of Novo Nordisk fell almost 5%. In the following video, health-care analyst Max Macaluso discusses what this news means for investors and how this drug fits into the obesity-drug market.
Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Your 3-Point Guide to Paying Off Debt
Want to shake that debt for good? Here's how.
Are You Paying More for Health Insurance Than You Should Be?
When it comes to picking healthcare coverage, too many of us opt for plans that don't make any financial sense.
These 3 Stocks Are Undeniably Cheap
After a sharp sell-off in recent years, these pipeline companies sell for shockingly low prices.